Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives

Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new c...

Full description

Saved in:
Bibliographic Details
Main Authors: Irene Testi, Giulia Claire Giudice, Giuseppe Salfi, Martino Pedrani, Sara Merler, Fabio Turco, Luigi Tortola, Ursula Vogl
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2024-11-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
Online Access:https://www.explorationpub.com/Journals/etat/Article/1002279
Tags: Add Tag
No Tags, Be the first to tag this record!